


# BeiGene Global Manufacturing Facilities

April 2024

### **BeiGene Manufacturing**

**Guangzhou Site** 



1. DS1 - 4 x 2kL Single-use Bioreactors

2. DS1 - 4 x 2kL KU Bio, DS2 - 8 x 2kL Single-use Bioreactors, DS3 8 x 5kL Stainless-steel bioreactors, DS4 2 x 500L Single-use Bioreactor 3. DS Clinical – 2 x 500L Single-use Bioreactors

MFG Overview Guangzhou Site Suzhou Site Hopewell Site Additional Capability

### Global Manufacturing Capabilities Overview



















PFS, Pre-filled Syringes; SUS, Single-Use System; SS, Stainless Steel

12.4-acre site

with 460,000 sq ft built

### **BeiGene**

### **Guangzhou - First Biologics Manufacturing Facility**



MFG Overview

Guangzhou Site

Suzhou Site



### **BeiGene**

### **Biologics and ADC Campus**







#### Drug **Substance**

#### Flexible Manufacturing Capabilities

- Total 65kL Cell Culture Capacity
  - Single-use System (2 x 500L, 12 x 2kL)
  - Stainless System (8 x 5kL)
  - Batch and Fed-batch







Drug **Products** 

#### **End-to-End DP Production Lines**

- Liquid Vials (clinical & commercial)
- Lyophilized Vials (mAb)
- Pre-filled Syringes (clinical & commercial)
- Label and Packaging







**ADCs** 

#### **Clinical & Commercial Production**

- ADC Conjugation room (250L stainless-steel tank) - Partnership with CMOs for Linker & Payload supply
- ADC Purification with Chromatograph & UF/DF
- DP Lyophilized Vials and Label & Packaging





Warehouse

#### **Equipped with Latest Technology**

- ASRS (Automatic Search & Retrieval System)
- Storage Conditions:

15 - 25°C, 2 - 8°C, - 40°C, - 70°C

Guangzhou Site

### Suzhou - Small Molecule Manufacturing Facility






MFG Overview Guangzhou Site Suzhou Site Hopewell Site Additional Capability

### **Small Molecule Production and R&D Campus**









#### **Flexible Manufacturing Capabilities**

- Total 300M Tablet & 300M Capsule Capacity (clinical & commercial)
- Primary Packaging (bottle & blister)
- Label & Packaging







Biological Drug Substance

#### Clinical and Pilot DS Production

- Total 1kL Cell Culture Capacity
  - Single-use System (2 x 500L)
  - Batch and Fed-batch
- Bispecific Antibody Production








### **Supports various product types**

Storage Conditions:
 15 - 25°C, 2 - 8°C, - 40°C, - 80°C

eiGene Confidential

### Hopewell - First U.S. Biologics Manufacturing Facility





MFG Overview Guangzhou Site Suzhou Site Hopewell Site Additional Capability

### **Expansion of State-of-the-Art Manufacturing Facility**









#### Drug Substance

#### **Manufacturing Capabilities**

- Total 8kL Cell Culture Capacity
  - Single-use System (4 x 2kL)
  - Batch, Fed-batch, and Perfusion
- Faster expansion through modular system
- Room reserved for additional 4 x 2kL line







Drug Products

#### **DP Production Lines**

- Isolators
- Liquid vials (clinical & commercial)
- Lyophilized Vials (clinical & commercial)
- Label & Packaging







#### **Equipped with Latest Technology**

- ASRS (Automatic Search & Retrieval System)
- Storage Conditions:
   2 8°C, 20°C, 70°C



Suzhou Site

### **High Standard Quality Management System**



Benchmarking ICH and US, European, and Chinese GMP standards to provide accessible and affordable good drugs for patients around the world

**Quality System: Internationally Recognized Top Standards** 

Policy

Global **Standard** 

Standard of **Operation (SOP)** 

**Working Instruction** 

Forms and Templates

30+ Approvals And Inspections In 5+ Years (US FDA, EMA, TGA, China NMPA, ANVISA, and more)









- **Successful Regulatory Approvals**
- **Inspections With Zero Critical Observations**

Guangzhou Site

### **QC Lab- Comprehensive Testing Capability**



Additional Capability

- Globalized Quality System enables the quick and efficient biologics CMC development
- **Phase-appropriate strategy** which meet international GMP regulatory requirement

### Bio PD/CMC and MST Capabilities





### **BIO PD & CMC**

Established Large Molecule Development Platform End to End (IND to Commercial)

Cell Line & Process Development

- · Cell Line Development
- Upstream & Downstream Development
- Analytical Development
- Formulation Development (Liquid, Lyo, PFS)
- Media Development
  - Proprietary Media (2x Titer output)

CMC Strategies and Management

- Fast to IND, BLA Strategies
- Ensure Timeline and Meet BLA Requirement (Global HA)
- Internal & External Programs Management

#### Due Diligence

- Assess CMC aspect of potential collaboration
- Contract negotiation around CMC Terms

mAbs, BsAb/TsAb, ADC, Fabs, Fusion, Recombinant protein



### **MST Lab**

Established BeiGene's Global Lab Capabilities
Well-equipped MST Lab With Expansion Opportunities

#### Technical Support

- Tech Transfer
- Process Validation
- Continuous Process Verification
- On The Floor Support

#### Lab Capability

Deviation Analysis



# CANCER HAS NO BORDERS. NEITHER DOWE

# Thank You

**Contacts**:

Business Development BDnotices@beigene.com